WHWilla Ann Hsueh

Willa Ann Hsueh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Willa Ann Hsueh has a total of 313 co-authors. Here are the top co-authors by number of shared publications:

  • David Bradley

    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Pennsylvania State Health Milton S. Hershey Medical Center, Hershey (D.B.).

    8 shared publications
  • Anahita Jalilvand

    Division of Trauma, Critical Care, and Burn, Department of Surgery, Wexner Medical Center, The Ohio State University 3 , Columbus, OH

    6 shared publications
  • Joey Liu

    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)

    6 shared publications
  • Alecia Blaszczak

    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)

    5 shared publications
  • Dharti Shantaram

    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)

    5 shared publications
  • Alan J. Smith

    Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Diabetes and Metabolism Research Center, The Ohio State University, Columbus (A.M.B., D.S., X.Y.R., V.P.W., J.L., A.J.S., A.A., C.D.B., D.M., R.G., W.A.H.)

    4 shared publications

Latest Publications

  • Adipose Tissue Immunosuppressive T Cells Regulate Atherosclerosis Development and Liver Fat Accumulation in Obesity

    by Alecia M. Blaszczak, Dharti Shantaram, Xilal Y. Rima, Valerie P. Wright, Joey Liu, Alan J. Smith, Anahita Jalilvand, Anastasiia Amari, Chase D. Bender, Dana Middendorf, et al.

    BACKGROUND: Obesity is associated with a loss of anti-inflammatory regulatory T cells (Tregs) in adipose tissue (AT), resulting in systemic inflammation. The adipocyte is a central modulator of CD4+T-cell subpopulations via antigen presentation through the MHCII (major histocompatibility complex class II). However, the role of adipocyte-induced AT inflammation due to changes in AT Tregs in obesity-related complications, such as atherosclerosis and metabolic-dysfunction-associated fatty liver disease (MAFLD), remains unknown. METHODS: Ldlr (low-density lipoprotein receptor) −/− knockout mice were crossed with adipocyte-specific MHCII knockout (aMHCll [adipocyte MHCII] −/− ) mice to study the effects of AT T-cell changes on atherosclerosis and MAFLD. Metabolic differences, atherosclerotic lesions, liver fat accumulation, and inflammation in adipose, splenic, aortic, and liver tissue were measured in 1-year-old aMHCll −/− Ldlr −/− mice fed a Western high-fat diet for 12 weeks. We used 1-year-old mice because, unlike young mice, they develop markedly accelerated atherosclerosis like humans. RESULTS: Loss of MHCII signaling in adipocytes prevented the obesity-mediated loss of AT Tregs, resulting in decreased insulin resistance, atherosclerosis, and MAFLD. In contrast, depletion of AT Tregs via IL (interleukin)-33 receptor–targeted immunotherapy with ST2 (suppression of tumorigenicity 2) reversed these improvements in Western high-fat diet–fed, 1-year-old aMHCll −/− Ldlr −/− mice, whereas increasing AT Tregs with IL-33 recombinant protein promoted similar beneficial effects as in aMHCll −/− Ldlr −/− mice. Because there were no alterations in splenic Tregs, these differences in atherosclerosis and MAFLD were AT Treg-mediated, independent of peripheral Tregs. Amelioration of insulin resistance, atherosclerosis, and MAFLD was diet- and adipocyte-dependent, as a low-fat, Western diet administered to 1-year-old aMHCll −/− Ldlr −/− mice and myeloid-adipo–specific MHCII knockout mice (m-aMHCll [myeloid-adipocyte MHCII] −/− ) ingesting a Western high-fat diet, had no effect on disease progression. CONCLUSIONS: These results suggest that AT immunosuppressive T cells play a pivotal role in regulating both atherosclerosis development and liver fat accumulation in obesity.


  • Open Access

    Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

    by Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, et al.

    A central challenge in nanomedicine is the scalable and precise engineering of nanocarriers that are simultaneously tunable, immune‐compatible, and capable of encapsulating diverse bioactive cargos. Extracellular vesicles (EVs), including native red blood cell‐derived EVs (RBCEVs), offer biocompatibility but remain limited by heterogeneous composition, low yield, poor scalability, and limited control in cargo loading. Here, we introduce a bottom‐up strategy for developing engineered red blood cell extracellular vesicles (eRBCEVs) through microfluidic diffusional mixing of purified RBC lipids and components. Parametric optimization through multi‐physics simulation enabled predictive control over flow rates, lipid concentration, and channel geometry. eRBCEVs exhibited comparable encapsulation efficiency across molecular cargos of distinct sizes and properties, including oligonucleotides, gold nanoparticles, hemoglobin, erythrocruorin (∼3.6 MDa), and full adeno‐associated virus (AAV ∼25 nm) particles, validated through cryo‐EM, chemical mapping, and high‐resolution TIRFM. Surface conjugation with CD47 peptide was established for comparison with RBCEVs; the bio‐conjugations with α‐PD‐L1 antibodies yielded functionalized vesicles with uptake in PD‐L1‐positive human tumor organoids. In vivo biodistribution and pharmacokinetic analysis in mice demonstrated sustained circulation and tissue distribution in the liver, spleen, and lungs. Neutrophil activation and macrophage uptake assays confirmed minimal immunogenicity compared to conventional particles and free‐protein controls. Collectively, our platform enables the scalable synthesis of customizable eRBCEVs that preserve RBC lipid features, support cargo flexibility, and potential for scale‐up. This work establishes eRBCEVs as a next‐generation therapeutic platform for programmable, patient‐specific delivery in gene therapy, immunomodulation, and translational nanomedicine.


  • Open Access

    Tunable self-assembling cellular microarray for single-neutrophil vital and suicidal extracellular traps

    by Jacob Doon-Ralls, Sophia Mayone, Xilal Y. Rima, Dharti Shantaram, Kim Truc Nguyen, Ajeet Singh, Bradley J. Needleman, Sabrena Noria, Stacy Brethauer, Kyle A. Perry, et al.

    A tunable micropatterned platform that enables single-cell analysis of NETosis with spatial precision using photopatterned bacterial extracellular vesicles.

  • The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism

    by Dharti Shantaram, Xilal Y. Rima, David Bradley, Joey Z. Liu, Valerie P. Wright, Anastasiia Amari, Anahita Jalilvand, Joseph Rottinghaus, Jaden M. Fernandes, Alan J. Smith, et al.

    Recent clinical trials testing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrated improved outcomes in obesity-associated complications, including cardiovascular events and hepatic steatosis. Despite their positive effects, whether the benefits of GLP-1 RAs are due to weight loss or are a direct therapeutic effect remains unclear. Therefore, we pair fed middle-aged low-density lipoprotein receptor knockout (Ldlr−/−) mice a Western high-fat diet to model complex atherosclerosis and metabolic dysfunction–associated fatty liver disease (MAFLD) and then administered dulaglutide or placebo twice a week for 6 weeks. Older compared with younger Ldlr−/− mice develop accelerated atherosclerosis resembling human lesions, and advanced MAFLD. Dulaglutide improved glucose tolerance and MAFLD independent of weight but had no effects on insulin sensitivity or atherosclerosis compared with weight-matched placebo-treated mice. The diminished hepatic steatosis was attributed to both decreased de novo lipogenesis and reduced adipose tissue lipolysis. These changes were associated with amelioration of inflammation and oxidative stress with a marked attenuation in M1-like macrophages in the liver. Therefore, dulaglutide has therapeutic effects on the liver that may further synergize with GLP-1 RA–mediated weight loss to reduce hepatic steatosis and inflammation, a major complication of obesity. ARTICLE HIGHLIGHTS: Glucagon-like peptide-1 receptor agonists are promising therapies in treating various obesity-associated diseases; however, the mechanisms are convoluted with the benefits of weight loss. Dulaglutide has weight-independent therapeutic effects on the liver, reducing hepatic steatosis and improving liver function. Dulaglutide reduces de novo lipogenesis, lipid droplet stability, inflammation, and oxidative stress in the liver and lipolysis in adipose tissue. Weight loss may play an important role in glucagon-like peptide-1 receptor agonists’ effect on decreasing coronary vascular disease risk.


  • Open Access

    Human Differentiated Adipocytes as Surrogate Mature Adipocytes for Adipocyte-Derived Extracellular Vesicle Analysis

    by Mangesh Dattu Hade, Bradley L. Butsch, Paola Loreto Palacio, Kim Truc Nguyen, Dharti Shantaram, Sabrena F. Noria, Stacy A. Brethauer, Bradley J. Needleman, Willa Hsueh, Eduardo Reátegui, et al.

    Obesity is a growing global health concern, contributing to diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. Adipose tissue dysfunction, characterized by abnormal adipokine secretion and chronic inflammation, plays a key role in these conditions. Adipose-derived extracellular vesicles (ADEVs) have emerged as critical mediators in obesity-related diseases. However, the study of mature adipocyte-derived EVs (mAdipo-EVs) is limited due to the short lifespan of mature adipocytes in culture, low EV yields, and the low abundance of these EV subpopulations in the circulation. Additionally, most studies rely on rodent models, which have differences in adipose tissue biology compared to humans. To overcome these challenges, we developed a standardized approach for differentiating human preadipocytes (preAdipos) into mature differentiated adipocytes (difAdipos), which produce high-yield, human adipocyte EVs (Adipo-EVs). Using visceral adipose tissue from bariatric surgical patients, we isolated the stromal vascular fraction (SVF) and differentiated preAdipos into difAdipos. Brightfield microscopy revealed that difAdipos exhibited morphological characteristics comparable to mature adipocytes (mAdipos) directly isolated from visceral adipose tissue, confirming their structural similarity. Additionally, qPCR analysis demonstrated decreased preadipocyte markers and increased mature adipocyte markers, further validating successful differentiation. Functionally, difAdipos exhibited lipolytic activity comparable to mAdipos, supporting their functional resemblance to native adipocytes. We then isolated preAdipo-EVs and difAdipo-EVs using tangential flow filtration and characterized them using bulk and single EV analysis. DifAdipo-EVs displayed classical EV and adipocyte-specific markers, with significant differences in biomarker expression compared to preAdipo-EVs. These findings demonstrate that difAdipos serve as a reliable surrogate for mature adipocytes, offering a consistent and scalable source of adipocyte-derived EVs for studying obesity and its associated disorders.


  • Open Access

    Large-scale multi-omics analyses in Hispanic/Latino populations identify genes for cardiometabolic traits

    by Lauren E. Petty, Hung-Hsin Chen, Elizabeth G. Frankel, Wanying Zhu, Carolina G. Downie, Mariaelisa Graff, Phillip Lin, Priya Sharma, Xinruo Zhang, Alyssa C. Scartozzi, et al.

    Here, we present a multi-omics study of type 2 diabetes and quantitative blood lipid and lipoprotein traits conducted to date in Hispanic/Latino populations (nmax = 63,184). We conduct a meta-analysis of 16 type 2 diabetes and 19 lipid trait GWAS, identifying 20 genome-wide significant loci for type 2 diabetes, including one novel locus and novel signals at two known loci, based on fine-mapping. We also identify sixty-one genome-wide significant loci across the lipid/lipoprotein traits, including nine novel loci, and novel signals at 19 known loci through fine-mapping. Next, we analyze genetically regulated expression, perform Mendelian randomization, and analyze association with transcriptomic and proteomic measure using multi-omics data from a Hispanic/Latino population. Using this approach, we identify genes linked to type 2 diabetes and lipid/lipoprotein traits, including TMEM205 and NEDD9 for HDL cholesterol, TREH for triglycerides, and ANXA4 for type 2 diabetes.


  • Open Access

    Obesity-associated microbiomes instigate visceral adipose tissue inflammation by recruitment of distinct neutrophils

    by Dharti Shantaram, Rebecca Hoyd, Alecia M. Blaszczak, Linda Antwi, Anahita Jalilvand, Valerie P. Wright, Joey Liu, Alan J. Smith, David Bradley, William Lafuse, et al.

    Neutrophils are increasingly implicated in chronic inflammation and metabolic disorders. Here, we show that visceral adipose tissue (VAT) from individuals with obesity contains more neutrophils than in those without obesity and is associated with a distinct bacterial community. Exploring the mechanism, we gavaged microbiome-depleted mice with stool from patients with and without obesity during high-fat or normal diet administration. Only mice receiving high-fat diet and stool from subjects with obesity show enrichment of VAT neutrophils, suggesting donor microbiome and recipient diet determine VAT neutrophilia. A rise in pro-inflammatory CD4+ Th1 cells and a drop in immunoregulatory T cells in VAT only follows if there is a transient spike in neutrophils. Human VAT neutrophils exhibit a distinct gene expression pattern that is found in different human tissues, including tumors. VAT neutrophils and bacteria may be a novel therapeutic target for treating inflammatory-driven complications of obesity, including insulin resistance and colon cancer.


  • Open Access

    Loss of Paneth cells dysregulates gut ILC subsets and enhances weight gain response to high fat diet in a mouse model

    by Marisa R. Joldrichsen, Eunsoo Kim, Haley E. Steiner, Yea Ji Jeong, Christopher Premanandan, Willa Hsueh, Ouliana Ziouzenkova, Estelle Cormet-Boyaka, Prosper N. Boyaka

    Obesity has been associated with dysbiosis, but innate mechanisms linking intestinal epithelial cell subsets and obesity remain poorly understood. Using mice lacking Paneth cells (Sox9 ΔIEC mice), small intestinal epithelial cells specialized in the production of antimicrobial products and cytokines, we show that dysbiosis alone does not induce obesity or metabolic disorders. Loss of Paneth cells reduced ILC3 and increased ILC2 numbers in the intestinal lamina propria. High-fat diet (HFD) induced higher weight gain and more severe metabolic disorders in Sox9 ΔIEC mice. Further, HFD enhances the number of ILC1 in the intestinal lamina propria of Sox9 ΔIEC mice and increases intestinal permeability and the accumulation of immune cells (inflammatory macrophages and T cells, and B cells) in abdominal fat tissues of obese Sox9 ΔIEC . Transplantation of fecal materials from Sox9 ΔIEC mice in germ-free mice before HFD further confirmed the regulatory role of Paneth cells for gut ILC subsets and the development of obesity.


  • Open Access

    Orchestration of the Adipose Tissue Immune Landscape by Adipocytes

    by David Bradley, Tuo Deng, Dharti Shantaram, Willa A. Hsueh

    Obesity is epidemic and of great concern because of its comorbid and costly inflammatory-driven complications. Extensive investigations in mice have elucidated highly coordinated, well-balanced interactions between adipocytes and immune cells in adipose tissue that maintain normal systemic metabolism in the lean state, while in obesity, proinflammatory changes occur in nearly all adipose tissue immune cells. Many of these changes are instigated by adipocytes. However, less is known about obesity-induced adipose-tissue immune cell alterations in humans. Upon high-fat diet feeding, the adipocyte changes its well-known function as a metabolic cell to assume the role of an immune cell, orchestrating proinflammatory changes that escalate inflammation and progress during obesity. This transformation is particularly prominent in humans. In this review, we ( a) highlight a leading and early role for adipocytes in promulgating inflammation, ( b) discuss immune cell changes and the time course of these changes (comparing humans and mice when possible), and ( c) note how reversing proinflammatory changes in most types of immune cells, including adipocytes, rescues adipose tissue from inflammation and obese mice from insulin resistance.


  • Open Access

    Interferon gamma mediates the reduction of adipose tissue regulatory T cells in human obesity

    by David Bradley, Alan J. Smith, Alecia Blaszczak, Dharti Shantaram, Stephen M. Bergin, Anahita Jalilvand, Valerie Wright, Kathleen L. Wyne, Revati S. Dewal, Lisa A. Baer, et al.

    Decreased adipose tissue regulatory T cells contribute to insulin resistance in obese mice, however, little is known about the mechanisms regulating adipose tissue regulatory T cells numbers in humans. Here we obtain adipose tissue from obese and lean volunteers. Regulatory T cell abundance is lower in obese vs. lean visceral and subcutaneous adipose tissue and associates with reduced insulin sensitivity and altered adipocyte metabolic gene expression. Regulatory T cells numbers decline following high-fat diet induction in lean volunteers. We see alteration in major histocompatibility complex II pathway in adipocytes from obese patients and after high fat ingestion, which increases T helper 1 cell numbers and decreases regulatory T cell differentiation. We also observe increased expression of inhibitory co-receptors including programmed cell death protein 1 and OX40 in visceral adipose tissue regulatory T cells from patients with obesity. In human obesity, these global effects of interferon gamma to reduce regulatory T cells and diminish their function appear to instigate adipose inflammation and suppress adipocyte metabolism, leading to insulin resistance.